Randomized phase II study of duligotuzumab (MEHD7945A) vs. cetuximab in squamous cell carcinoma of the head and neck (MEHGAN study)

Frontiers in Oncology

Volumn 6, Issue OCT, 2016, Pages

  Fayette, Jérôme ^a   Wirth, Lori ^b   Oprean, Cristina ^c   Udrea, Anghel ^d   Jimeno, Antonio ^e   Rischin, Danny ^f   Nutting, Christopher ^g   Harari, Paul M ^h   Csoszi, Tibor ⁱ   Cernea, Dana ^j   O'Brien, Paul ^k   Hanley, William D ^l   Kapp, Amy V ^l   Anderson, Maria ^l   Penuel, Elicia ^l   McCall, Bruce ^l   Pirzkall, Andrea ^l   Vermorken, Jan B ^m  

^a UNIVERSITÉ DE LYON   (France)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c Oncomed SRL Timisoara   (Romania)

^d Medisprof SRL   (Romania)

^e UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^f UNIVERSITY OF MELBOURNE   (Australia)

^g INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^h University of Wisconsin Health   (United States)

ⁱ Jász Nagykun Szolnok Megyei Hetényi Géza Kórház   (Hungary)

^j THE ONCOLOGY INSTITUTE PROF DR ION CHIRICUTA   (Romania)

^k MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^l GENENTECH INC   (United States)

^m ANTWERP UNIVERSITY HOSPITAL   (Belgium)

more..

Author keywords

Cetuximab; Duligotuzumab; EGFR; HER3; HPV; MEHD7945A; NRG1; SCCHN

Indexed keywords

CETUXIMAB; DULIGOTUZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 3;

ADULT; ARTICLE; COMPARATIVE EFFECTIVENESS; DISEASE COURSE; FEVER; GASTROINTESTINAL DISEASE; HEAD AND NECK CARCINOMA; HEADACHE; HUMAN; INFUSION RELATED REACTION; INTERACTIVE VOICE RESPONSE SYSTEM; LOADING DRUG DOSE; METABOLIC DISORDER; MULTICENTER STUDY (TOPIC); OPEN STUDY; OVERALL SURVIVAL; PHARMACOKINETIC PARAMETERS; PHASE 2 CLINICAL TRIAL; PREVALENCE; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RASH; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA;

EID: 84997236623     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2016.00232     Document Type: Article

References (27)

1. Brand TM, Iida M, Li C, Wheeler DL. The nuclear epidermal growth factor receptor signaling network and its role in cancer. Discov Med (2011) 12(66):419-32.
2. Kalyankrishna S, Grandis JR. Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol (2006) 24(17):2666-72. doi: 10.1200/jco.2005.04.8306.
3. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene (2006) 366(1):2-16. doi:10.1016/j.gene.2005.10.018.
4. Vermorken JB, Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol (2007) 25(16):2171-7. doi:10.1200/jco.2006.06.7447.
5. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med (2008) 359(11):1116-27. doi:10.1056/NEJMoa0802656.
6. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol (2010) 11(1):21-8. doi:10.1016/s1470-2045(09)70311-0.
7. Tinhofer I, Klinghammer K, Weichert W, Knodler M, Stenzinger A, Gauler T, et al. Expression of amphiregulin and EGFRvIII affect outcome of patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment. Clin Cancer Res (2011) 17(15):5197-204. doi:10.1158/1078-0432.ccr-10-3338.
8. Yonesaka K, Zejnullahu K, Okamoto I, Satoh T, Cappuzzo F, Souglakos J, et al. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med (2011) 3(99):99ra86. doi:10.1126/scitranslmed.3002442.
9. Jain A, Penuel E, Mink S, Schmidt J, Hodge A, Favero K, et al. HER kinase axis receptor dimer partner switching occurs in response to EGFR tyrosine kinase inhibition despite failure to block cellular proliferation. Cancer Res (2010) 70(5):1989-99. doi:10.1158/0008-5472.can-09-3326.
10. Wheeler DL, Huang S, Kruser TJ, Nechrebecki MM, Armstrong EA, Benavente S, et al. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene (2008) 27(28):3944-56. doi:10.1038/onc.2008.19.
11. Li C, Iida M, Dunn EF, Ghia AJ, Wheeler DL. Nuclear EGFR contributes to acquired resistance to cetuximab. Oncogene (2009) 28(43):3801-13. doi:10.1038/onc.2009.234.
12. Wilson TR, Lee DY, Berry L, Shames DS, Settleman J. Neuregulin-1-mediated autocrine signaling underlies sensitivity to HER2 kinase inhibitors in a subset of human cancers. Cancer Cell (2011) 20(2):158-72. doi:10.1016/j.ccr.2011.07.011.
13. Shames DS, Carbon J, Walter K, Jubb AM, Kozlowski C, Januario T, et al. High heregulin expression is associated with activated HER3 and may define an actionable biomarker in patients with squamous cell carcinomas of the head and neck. PLoS One (2013) 8(2):e56765. doi:10.1371/journal.pone.0056765.
14. Sliwkowski MX, Schaefer G, Akita RW, Lofgren JA, Fitzpatrick VD, Nuijens A, et al. Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. J Biol Chem (1994) 269(20):14661-5.
15. Bostrom J, Yu SF, Kan D, Appleton BA, Lee CV, Billeci K, et al. Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science (2009) 323(5921):1610-4. doi:10.1126/science.1165480.
16. Schaefer G, Haber L, Crocker LM, Shia S, Shao L, Dowbenko D, et al. A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell (2011) 20(4):472-86. doi:10.1016/j.ccr.2011.09.003.
17. Huang S, Li C, Sliwkowski MX, Harari PM. MEHD7945A, an EGFR/ErbB3 dual specific antibody, overcomes acquired resistance to EGFR inhibitors in head and neck and lung tumors. Cancer Res (2011) 71(8 Suppl):637-637. doi:10.1158/1538-7445.AM2011-637.
18. Juric D, Dienstmann R, Cervantes A, Hidalgo M, Messersmith W, Blumenschein GR Jr, et al. Safety and pharmacokinetics/pharmacodynamics of the first-in-class dual action HER3/EGFR antibody MEHD7945A in locally advanced or metastatic epithelial tumors. Clin Cancer Res (2015) 21(11):2462-70. doi:10.1158/1078-0432.ccr-14-2412.
19. ClinicalTrials.gov. A Study of MEHD7945A Versus Cetuximab in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck. ClinicalTrials.gov (2016). Available from: https://clinicaltrials.gov/ct2/show/NCT01577173.
20. Seiwert TY, Fayette J, Cupissol D, Del Campo JM, Clement PM, Hitt R, et al. A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck. Ann Oncol (2014) 25(9):1813-20. doi:10.1093/annonc/mdu216.
21. Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med (2015) 372(8):724-34. doi:10.1056/NEJMoa1413513.
22. Patel D, Lahiji A, Patel S, Franklin M, Jimenez X, Hicklin DJ, et al. Monoclonal antibody cetuximab binds to and down-regulates constitutively activated epidermal growth factor receptor vIII on the cell surface. Anticancer Res (2007) 27(5a):3355-66.
23. Li C, Huang S, Armstrong EA, Francis DM, Werner LR, Sliwkowski MX, et al. Antitumor effects of MEHD7945A, a dual-specific antibody against EGFR and HER3, in combination with radiation in lung and head and neck cancers. Mol Cancer Ther (2015) 14(9):2049-59. doi:10.1158/1535-7163.mct-15-0155.
24. Hegde GV, de la Cruz CC, Chiu C, Alag N, Schaefer G, Crocker L, et al. Blocking NRG1 and other ligand-mediated Her4 signaling enhances the magnitude and duration of the chemotherapeutic response of non-small cell lung cancer. Sci Transl Med (2013) 5(171):171ra118. doi:10.1126/scitranslmed.3004438.
25. Clement P, Machiels J, Wirth L, Specenier P, Seiwert T, Mardjuadi F, et al. Phase 1b study of MEHD7945A (DULIGOTUZUMAB) plus cisplatin/fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of head and neck. Presented at the European Society for Medical Oncology. (2014).
26. Jimeno A, Machiels JP, Wirth L, Specenier P, Seiwert TY, Mardjuadi F, et al. Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck. Cancer (2016). doi:10.1002/cncr.30256.
27. Machiels JP, Haddad RI, Fayette J, Licitra LF, Tahara M, Vermorken JB, et al. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. Lancet Oncol (2015) 16(5):583-94. doi:10.1016/s1470-2045(15)70124-5.